Immobilization of Denosumab on Titanium Affects Osteoclastogenesis of Human Peripheral Blood Monocytes.
Felicitas BeckEliza S HartmannMiriam I KoehlerJulia I RedekerSabine SchluesselBaerbel SchmittAndreas FottnerMarina UngerMartijn van GriensvenJan MichaelBurkhard SummerKarl-Heinz KunzelmannRene BeutnerDieter ScharnweberPaul J KostenuikSusanne Mayer-WagnerPublished in: International journal of molecular sciences (2019)
Immobilization of proteins has been examined to improve implant surfaces. In this study, titanium surfaces were modified with nanofunctionalized denosumab (cDMAB), a human monoclonal anti-RANKL IgG. Noncoding DNA oligonucleotides (ODN) served as linker molecules between titanium and DMAB. Binding and release experiments demonstrated a high binding capacity of cDMAB and continuous release. Human peripheral mononuclear blood cells (PBMCs) were cultured in the presence of RANKL/MCSF for 28 days and differentiated into osteoclasts. Adding soluble DMAB to the medium inhibited osteoclast differentiation. On nanofunctionalized titanium specimens, the osteoclast-specific TRAP5b protein was monitored and showed a significantly decreased amount on cDMAB-titanium in PBMCs + RANKL/MCSF. PBMCs on cDMAB-titanium also changed SEM cell morphology. In conclusion, the results indicate that cDMAB reduces osteoclast formation and has the potential to reduce osteoclastogenesis on titanium surfaces.
Keyphrases
- bone loss
- endothelial cells
- peripheral blood
- induced pluripotent stem cells
- stem cells
- bone mineral density
- induced apoptosis
- risk assessment
- nuclear factor
- lps induced
- binding protein
- escherichia coli
- cystic fibrosis
- oxidative stress
- cell cycle arrest
- small molecule
- pseudomonas aeruginosa
- transcription factor
- climate change
- toll like receptor
- protein protein
- magnetic nanoparticles
- candida albicans